Vaginal progesterone for the prevention of neonatal Respiratory Distress Syndrome - a randomised controlled trial

呼吸窘迫综合征是早产儿（怀孕不到34周）的一个重要问题。对于这些婴儿，超过90%的婴儿需要呼吸支持。这些婴儿死亡的风险也增加了，幸存者有长期残疾的风险。目前尚不确定是否给予阴道孕酮治疗怀孕妇女谁有过早产可以减少这些风险。这项随机对照试验将评估阴道孕酮治疗对早产风险妇女的使用，作为降低新生儿呼吸窘迫综合征风险和改善婴儿结局的一种手段。

Respiratory Distress Syndrome is a significant problem for babies born very preterm (at less than 34 weeks of pregnancy). For these babies, over 90% will require support for their breathing. These babies are also at increased risk of dying, and in survivors, there is a risk of long-term disability. It is uncertain if giving vaginal progesterone therapy during pregnancy to women who have had a previous preterm birth can reduce these risks. This randomised controlled trial will assess the use of vaginal progesterone therapy for women at risk of preterm birth as a means of reducing the risk of neonatal Respiratory Distress Syndrome and improving the outcomes of their babies.